Weekly intravenous and intraperitoneal paclitaxel combined with S-1 for malignant ascites due to advanced gastric cancer

Oncology

Volumn 78, Issue 1, 2010, Pages 40-46

  Kitayama, Joji ^a   Ishigami, Hironori ^a   Kaisaki, Shoichi ^a   Hidemura, Akio ^a   Kato, Masahiro ^a   Otani, Kensuke ^a   Kamei, Takao ^a   Soma, Daisuke ^a   Miyato, Hideyo ^a   Yamashita, Hiroharu ^a   Nagawa, Hirokazu ^a  

^a UNIVERSITY OF TOKYO   (Japan)

Author keywords

Ascites; Ascitic fluid volume; Gastric cancer; Intraperitoneal paclitaxel administration; Malignant ascites; Paclitaxel; S 1

Indexed keywords

5 CHLORO 2,4 DIHYDROXYPYRIDINE PLUS OXONATE POTASSIUM PLUS TEGAFUR; CISPLATIN; PACLITAXEL;

ABDOMINAL PAIN; ADULT; ADVANCED CANCER; AGED; ANOREXIA; ARTICLE; ASCITES; ASCITES FLUID; CANCER COMBINATION CHEMOTHERAPY; CANCER PATIENT; CLINICAL EVALUATION; COMPUTER ASSISTED TOMOGRAPHY; DIARRHEA; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG WITHDRAWAL; FEMALE; HUMAN; LEUKOPENIA; MAJOR CLINICAL STUDY; MALE; MEASUREMENT; MULTIPLE CYCLE TREATMENT; NAUSEA; NEUTROPENIA; OUTCOME ASSESSMENT; OVERALL SURVIVAL; PERITONEAL CATHETER; PERITONEAL CAVITY; PREDICTOR VARIABLE; PRIORITY JOURNAL; PROGNOSIS; STOMACH CANCER; TREATMENT DURATION; TREATMENT RESPONSE;

ADMINISTRATION, ORAL; ADULT; AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; ASCITES; DRUG ADMINISTRATION SCHEDULE; DRUG COMBINATIONS; FEMALE; HUMANS; INFUSIONS, INTRAVENOUS; INJECTIONS, INTRAPERITONEAL; MALE; MIDDLE AGED; OXONIC ACID; PACLITAXEL; PERITONEAL NEOPLASMS; STOMACH NEOPLASMS; SURVIVAL ANALYSIS; TEGAFUR; TOMOGRAPHY, X-RAY COMPUTED;

EID: 77449137078     PISSN: 00302414     EISSN: None     Source Type: Journal    
DOI: 10.1159/000290955     Document Type: Article

References (23)

1. Ajani JA: Standard chemotherapy for gastric carcinoma: is it a myth? J Clin Oncol 2000; 18: 4001-4003.
2. Yan TD, Black D, Sugarbaker PH, Zhu J, Yonemura Y, Petrou G, et al: A systematic review and meta-analysis of the randomized controlled trials on adjuvant intraperitoneal chemotherapy for resectable gastric cancer. Ann Surg Oncol 2007; 14: 2702-2713.
3. Ohtsu A, Yoshida S, Saijo N: Disparities in gastric cancer chemotherapy between the East and West. J Clin Oncol 2006; 24: 2188-2196.
4. Yamao T, Shimada Y, Shirao K, Ohtsu A, Ikeda N, Hyodo I, et al: Phase II study of sequential methotrexate and 5-fluorouracil chemotherapy against peritoneally disseminated gastric cancer with malignant ascites: a report from the Gastrointestinal Oncology Study Group of the Japan Clinical Oncology Group, JCOG 9603 Trial. Jpn J Clin Oncol 2004; 34: 316-322.
5. Oh SY, Kwon HC, Lee S, Lee DM, Yoo HS, Kim SH, et al: A phase II study of oxaliplatin with low-dose leucovorin and bolus and continuous infusion 5-fluorouracil (modified FOLFOX-4) for gastric cancer patients with malignant ascites. Jpn J Clin Oncol 2007; 37: 930-935.
6. Yonemura Y, Kawamura T, Bandou E, Takahashi S, Sawa T, Matsuki N: Treatment of peritoneal dissemination from gastric cancer by peritonectomy and chemohyperthermic peritoneal perfusion. Br J Surg 2005; 92: 370-375.
7. Markman M, Brady MF, Spirtos NM, Hanjani P, Rubin SC: Phase II trial of intraperitoneal paclitaxel in carcinoma of the ovary, tube, and peritoneum: a Gynecologic Oncology Group Study. J Clin Oncol 1998; 16: 2620-2624.
8. Zylberberg B, Dormont D, Madelenat P, Darai E: First-line intraperitoneal cisplatin-paclitaxel and intravenous ifosfamide in stage IIIc ovarian epithelial cancer. Eur J Gynaecol Oncol 2004; 25: 327-332.
9. Mohamed F, Sugarbaker PH: Intraperitoneal taxanes. Surg Oncol Clin N Am 2003; 12: 825-833.
10. Armstrong DK, Bundy B, Wenzel L, Huang HQ, Baergen R, Lele S, et al: Intraperitoneal cisplatin and paclitaxel in ovarian cancer. N Engl J Med 2006; 354: 34-43.
11. Tamura S, Miki H, Nakata K, Takiuchi D, Okada K, Nakahira S, et al: Intraperitoneal administration of paclitaxel and oral S-1 for a patient with peritoneal dissemination and hydronephrosis due to advanced gastric cancer. Gastric Cancer 2007; 10: 251-255.
12. Kodera Y, Ito Y, Ito S, Ohashi N, Mochizuki Y, Yamamura Y, et al: Intraperitoneal paclitaxel: a possible impact of regional delivery for prevention of peritoneal carcinomatosis in patients with gastric carcinoma. Hepatogastroenterology 2007; 54: 960-963.
13. Ishigami H, Kitayama J, Otani K, Kamei T, Soma D, Miyato H, et al: Phase I pharmacokinetic study of weekly intravenous and intraperitoneal paclitaxel combined with S-1 for advanced gastric cancer. Oncology 2009; 76: 311-314.
14. Japanese Gastric Cancer Association: Japanese Classification of Gastric Carcinoma - 2nd English Edition. Gastric Cancer 1998; 1: 10-24.
15. Fujii S, Kitayama J, Kaisaki S, Sasaki S, Seto Y, Tominaga O, et al: Carcinoembryonic antigen mRNA in abdominal cavity as a useful predictor of peritoneal recurrence of gastric cancer with serosal exposure. J Exp Clin Cancer Res 2002; 21: 547-553.
16. Koizumi W, Narahara H, Hara T, Takagane A, Akiya T, Takagi M, et al: S-1 plus cisplatin versus S-1 alone for first-line treatment of advanced gastric cancer (SPIRITS trial): a phase III trial. Lancet Oncol 2008; 9: 215-221.
17. Lenz HJ, Lee FC, Haller DG, Singh D, Benson AB 3rd, Strumberg D, et al: Extended safety and efficacy data on S-1 plus cisplatin in patients with untreated, advanced gastric carcinoma in a multicenter phase II study. Cancer 2007; 109: 33-40.
18. Chang YF, Li LL, Wu CW, Liu TY, Lui WY, P'Eng FK, et al: Paclitaxel-induced apoptosis in human gastric carcinoma cell lines. Cancer 1996; 77: 14-18.
19. Paque F, Luder HU, Sener B, Zehnder M: Tubular sclerosis rather than the smear layer impedes dye penetration into the dentine of endodontically instrumented root canals. Int Endod J 2006; 39: 18-25.
20. Grider MH, Chen Q, Shine HD: Semi-automated quantification of axonal densities in labeled CNS tissue. J Neurosci Methods 2006; 155: 172-179.
21. Ueda S, Hironaka S, Boku N, Fukutomi A, Yoshino T, Onozawa Y: Combination chemotherapy with irinotecan and cisplatin in pretreated patients with unresectable or recurrent gastric cancer. Gastric Cancer 2006; 9: 203-207.
22. Hironaka S, Zenda S, Boku N, Fukutomi A, Yoshino T, Onozawa Y: Weekly paclitaxel as second-line chemotherapy for advanced or recurrent gastric cancer. Gastric Cancer 2006; 9: 14-18.
23. Lordick F, Ott K, Weitz J, Jager D: The evolving role of catumaxomab in gastric cancer. Expert Opin Biol Ther 2008; 8: 1407-1415.